Jacobs Levy Equity Management, Inc Protagonist Therapeutics, Inc Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 128,654 shares of PTGX stock, worth $5.06 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
128,654
Previous 129,011
0.28%
Holding current value
$5.06 Million
Previous $4.47 Million
29.33%
% of portfolio
0.02%
Previous 0.02%
Shares
15 transactions
Others Institutions Holding PTGX
# of Institutions
248Shares Held
56.7MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$230 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$226 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$213 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$166 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$125 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.93B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...